Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance.

MLA

Yamamoto, Sena, et al. “Financial Toxicity and Patient Experience Associated with Financial Burden of Molecular-Targeted and Immune Therapies for Cancer: An Observational Study under Public Health Insurance.” International Journal of Clinical Oncology, vol. 29, no. 4, Apr. 2024, pp. 417–26. EBSCOhost, https://doi.org/10.1007/s10147-024-02479-2.

APA

Yamamoto, S., Kondoh, C., Nakagoshi, H., Kakumen, M., Yasuhara, K., Nakai, M., Kodani, N., Sunda, K., Higashide, C., Katayama, M., & Arao, H. (2024). Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance. International Journal of Clinical Oncology, 29(4), 417–426. https://doi.org/10.1007/s10147-024-02479-2

Chicago

Yamamoto, Sena, Chiharu Kondoh, Hideko Nakagoshi, Mayuko Kakumen, Kana Yasuhara, Mayumi Nakai, Naoko Kodani, et al. 2024. “Financial Toxicity and Patient Experience Associated with Financial Burden of Molecular-Targeted and Immune Therapies for Cancer: An Observational Study under Public Health Insurance.” International Journal of Clinical Oncology 29 (4): 417–26. doi:10.1007/s10147-024-02479-2.